Fig. 3: Inhibition of TGM2 reduces patient-derived tumorsphere formation in vitro by an induction of p53-mediated apoptosis. | Cancer Gene Therapy

Fig. 3: Inhibition of TGM2 reduces patient-derived tumorsphere formation in vitro by an induction of p53-mediated apoptosis.

From: Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target

Fig. 3: Inhibition of TGM2 reduces patient-derived tumorsphere formation in vitro by an induction of p53-mediated apoptosis.The alternative text for this image may have been generated using AI.

A–D SW480 and CaCo2 cells were treated with LDN27219 (1 µM and 2 µM), Tyrphostin (10 µM and 100 µM) or DMSO and subsequently analyzed. A Cell expansion after treatment. Shown are the mean fold changes of cell number normalized to DMSO control 72 h after treatment. B Mean number of tumorspheres counted 7 days after treatment. C Percentage of apoptotic cells determined by Annexin V/7-AAD staining 72 h after treatment. D Mean number of p53(S15) positive SW480 cells detected by Flow cytometry. E Isolated tumor cells derived from freshly resected CRC patient specimens were treated with LDN27219, Tyrphostin or DMSO and the number of formed tumorspheres was determined at day 14 (n = 5 CRC patients). F Representative photomicrographs of tumorspheres. Scale bar, 100 µm. Data are expressed as mean ± SD of at least three independent experiments. Significance determined using Multiple t-test or Mann-Whitney-U test.

Back to article page